Synopsis:
Blue Jet Healthcare Ltd is in focus after its promoter Akshay Bansarilal offered 6.19 p.c stake by means of OFS.
A small-cap pharmaceutical firm engaged in manufacturing and promoting intermediates and APIs for healthcare merchandise, is within the highlight after its promoter offered 6.19 p.c stake by means of Provide on the market.
With the market capitalization of Rs. 12,354.21 crore, the shares of Blue Jet Healthcare Ltd is buying and selling at Rs. 712.25, down by 0.66 p.c from its earlier day shut worth of Rs. 716.95. The inventory has made an intraday low of Rs. 706.
What’s the Information?
Akshay Bansarilal Arora, one of many promoters of Blue Jet Healthcare Restricted, offered 10,734,529 fairness shares, representing a 6.19 p.c stake, on September 10, 2025 and September 11, 2025, by means of an Provide for Sale (OFS) to adjust to SEBI’s minimal public shareholding (MPS) requirement. The ground worth for the supply was set at Rs. 675 per share.
Additionally Learn: Infra inventory in focus after receiving ₹8 Cr order from Torrent Fuel Jaipur for gasoline pipeline mission
In regards to the Firm
Blue Jet Healthcare Restricted, integrated in 1968 and headquartered in Thane, is a pharmaceutical firm engaged in manufacturing and promoting intermediates and APIs for healthcare merchandise.
Its choices embody distinction media intermediates, area of interest APIs, CDMO/CMO providers, and end-to-end options from course of growth to commercialization of NCEs, superior intermediates, and constructing blocks.
The corporate additionally develops and markets saccharin and its salts, with operations throughout India, Europe, the U.S., and different worldwide markets. As of FY25, the corporate has a commercialized product portfolio of 51 merchandise and a complete response capability of 1,177.9 KL throughout three manufacturing services.
Monetary Outlook
In Q1FY26, income rose 4 p.c QoQ to Rs. 355 crore from Rs. 340 crore in Q4FY25 and 118 p.c YoY from Rs. 163 crore in Q1FY25. Working revenue got here in at Rs. 121 crore, down 14 p.c QoQ from Rs. 140 crore however up 175 p.c YoY from Rs. 44 crore.
Internet revenue stood at Rs. 91 crore, declining 17 p.c QoQ from Rs. 110 crore but surging 139 p.c YoY from Rs. 38 crore. EPS in Q1FY26 was Rs. 5.26, in contrast with Rs. 6.35 in Q4FY25 and Rs. 2.18 in Q1FY25. The outcomes spotlight robust annual development in income and profitability, although sequential efficiency was weaker because of contraction in working margins.
A return on fairness (ROE) of about 30.2 p.c, a return on capital employed (ROCE) of about 39.8 p.c and debt to fairness ratio at 0.02 display the corporate’s monetary place. In the meanwhile, the corporate’s P/E ratio is 34.4x barely greater as in comparison with its trade P/E 33.6x.
Written by Akshay Sanghavi
Disclaimer
The views and funding ideas expressed by funding consultants/broking homes/ranking businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Traders should due to this fact train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the creator will not be accountable for any losses induced on account of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
